INTRODUCTION: Micro- and macrovascular complications of diabetes are leading morbidities in the world population. They are responsible not only for increased mortality but also severe disabilities, which jeopardize quality of life (e.g., blindness, walking limitations, and renal failure requiring dialysis). The new antidiabetic agents (e.g., glucagon-like peptide 1 receptor agonists and sodium-glucose cotransporter inhibitors) are increasingly recognized as breakthrough agents in the treatment of diabetes and prevention of diabetic complications. However, drugs effective in preventing and treating diabetic disabilities are still needed and sulodexide could be one of those able to address the unmet clinical needs of the new antidiabetic agents. METHODS: We searched MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials, and the World Health Organization (WHO) International Clinical Trials Registry Platform Search Portal. We also manually searched potentially relevant journals, conference proceedings, and journal supplements. Any study monitoring any effect of sulodexide in subjects with diabetes, in relation to renal, vascular, and ocular complication, was considered. Treatment effects were estimated using standardized mean differences (SMDs), mean differences (MDs), and risk ratios (RRs), as appropriate. We calculated 95% confidence interval (CIs) and heterogeneity (Q, tau, and I2). RESULTS: The search found 45 studies with 2817 participants (mean age 57 years; 63% male). The 26 randomized controlled studies included 2074 participants (mean age 58.8 years; 66% male). Sulodexide reduced the impact of diabetic retinopathy; increased the pain-free and maximal walking distance in peripheral arterial disease; accelerated the healing of diabetes-associated trophic ulcers; and decreased the rate of albumin excretion in subjects with nephropathy. The risk of adverse events (AEs) was not different between sulodexide and controls. CONCLUSION: Sulodexide has a beneficial effect on the ocular, peripheral arterial disease, trophic ulcers, and renal complications of diabetes without increasing the risk of AEs.

Department B of Ophthalmology Hedi Rais Institute of Ophthalmology Faculty of Medicine of Tunis University of El Manar Tunis Tunisia

Division of Nephrology and Dialysis Ospedale Maggiore University of Verona Verona Italy

MATMED S R O Private Angiology Facility Hodonin Czech Republic

School of Specialisation in Hospital Pharmacy Department of Pharmaceutical Sciences University of Milan Milan Italy

Zobrazit více v PubMed

DeFronzo RA, Ferrannini E, Zimmet P, Alberti KGMM. International textbook of diabetes mellitus. 4. Hoboken: Wiley-Blackwell; 2015.

NCD Risk Factor Collaboration (NCD-RisC) Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. Lancet. 2016;387(10027):1513–1530. doi: 10.1016/S0140-6736(16)00618-8. PubMed DOI PMC

International Diabetes Federation. IDF Diabetes Atlas, 8th edition 2017. http://www.diabetesatlas.org. Accessed 9 Apr 2020.

GBD 2017 Disease and Injury Incidence and Prevalence Collaborators Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1789–1858. doi: 10.1016/S0140-6736(18)32279-7. PubMed DOI PMC

Hewitt J, Castilla Guerra L, Fernández-Moreno MC, Sierra C. Diabetes and stroke prevention: a review. Stroke Res Treat. 2012;2012:673187. doi: 10.1155/2012/673187. PubMed DOI PMC

Thiruvoipati T, Kielhorn CE, Armstrong EJ. Peripheral artery disease in patients with diabetes: epidemiology, mechanisms, and outcomes. World J Diabetes. 2015;6(7):961–969. doi: 10.4239/wjd.v6.i7.961. PubMed DOI PMC

Zoungas S, Arima H, Gerstein HC, et al. Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials. Lancet Diabetes Endocrinol. 2017;5(6):431–437. doi: 10.1016/S2213-8587(17)30104-3. PubMed DOI

Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358(6):580–591. doi: 10.1056/NEJMoa0706245. PubMed DOI

Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–657. doi: 10.1056/NEJMoa1611925. PubMed DOI

Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, Jensen T, Kofoed-Enevoldsen A. Albuminuria reflects widespread vascular damage. The Steno hypothesis. Diabetologia. 1989;32(4):219–226. doi: 10.1007/BF00285287. PubMed DOI

Dogné S, Flamion B, Caron N. Endothelial glycocalyx as a shield against diabetic vascular complications: involvement of hyaluronan and hyaluronidases. Arterioscler Thromb Vasc Biol. 2018;38(7):1427–1439. doi: 10.1161/ATVBAHA.118.310839. PubMed DOI PMC

Abaterusso C, Gambaro G. The role of glycosaminoglycans and sulodexide in the treatment of diabetic nephropathy. Treat Endocrinol. 2006;5(4):211–222. doi: 10.2165/00024677-200605040-00002. PubMed DOI

Weiss R, Niecestro R, Raz I. The role of sulodexide in the treatment of diabetic nephropathy. Drugs. 2007;67(18):2681–2696. doi: 10.2165/00003495-200767180-00004. PubMed DOI

Lewis EJ, Xu X. Abnormal glomerular permeability characteristics in diabetic nephropathy: implications for the therapeutic use of low-molecular weight heparin. Diabetes Care. 2008;31(Suppl 2):S202–S207. doi: 10.2337/dc08-s251. PubMed DOI

Masola V, Zaza G, Gambaro G. Sulodexide and glycosaminoglycans in the progression of renal disease. Nephrol Dial Transplant. 2014;29(Suppl 1):i74–i79. doi: 10.1093/ndt/gft389. PubMed DOI

Masola V, Zaza G, Onisto M, Lupo A, Gambaro G. Glycosaminoglycans, proteoglycans and sulodexide and the endothelium: biological roles and pharmacological effects. Int Angiol. 2014;33(3):243–254. PubMed

Carroll BJ, Piazza G, Goldhaber SZ. Sulodexide in venous disease. J Thromb Haemost. 2019;17(1):31–38. doi: 10.1111/jth.14324. PubMed DOI

Coccheri S, Mannello F. Development and use of sulodexide in vascular diseases: implications for treatment. Drug Des Dev Ther. 2013;8:49–65. doi: 10.2147/DDDT.S6762. PubMed DOI PMC

Yung S, Chau MK, Zhang Q, Zhang CZ, Chan TM. Sulodexide decreases albuminuria and regulates matrix protein accumulation in C57BL/6 mice with streptozotocin-induced type I diabetic nephropathy. PLoS One. 2013;8(1):e54501. doi: 10.1371/journal.pone.0054501. PubMed DOI PMC

Roshan-Milani S, Khalilpour J, Abdollahzade FA. The heparanase inhibitor (sulodexide) decreases urine glycosaminoglycan excretion and mitigates functional and histological renal damages in diabetic rats. Acta Med Bulg. 2019;46(2):41–46. doi: 10.2478/amb-2019-0017. DOI

Gambaro G, Cavazzana AO, Luzi P, et al. Glycosaminoglycans prevent morphological renal alterations and albuminuria in diabetic rats. Kidney Int. 1992;42(2):285–291. doi: 10.1038/ki.1992.288. PubMed DOI

Gambaro G, Venturini AP, Noonan DM, et al. Treatment with a glycosaminoglycan formulation ameliorates experimental diabetic nephropathy. Kidney Int. 1994;46(3):797–806. doi: 10.1038/ki.1994.335. PubMed DOI

Kristová V, Lísková S, Sotníková R, Vojtko R, Kurtanský A. Sulodexide improves endothelial dysfunction in streptozotocin-induced diabetes in rats. Physiol Res. 2008;57(3):491–494. PubMed

Li T, Liu X, Zhao Z, Ni L, Liu C. Sulodexide recovers endothelial function through reconstructing glycocalyx in the balloon-injury rat carotid artery model. Oncotarget. 2017;8(53):91350–91361. doi: 10.18632/oncotarget.20518. PubMed DOI PMC

Liu YN, Zhou J, Li T, et al. Sulodexide protects renal tubular epithelial cells from oxidative stress-induced injury via upregulating klotho expression at an early stage of diabetic kidney disease. J Diabetes Res. 2017;2017:4989847. doi: 10.1155/2017/4989847. PubMed DOI PMC

Song JW, Zullo JA, Liveris D, Dragovich M, Zhang XF, Goligorsky MS. Therapeutic restoration of endothelial glycocalyx in sepsis. J Pharmacol Exp Ther. 2017;361(1):115–121. doi: 10.1124/jpet.116.239509. PubMed DOI PMC

Li T, Liu C. Sulodexide recovers endothelial function through reconstructing glycocalyx in the balloon-injury rat carotid artery model. Int Angiol. 2018;37:72. PubMed PMC

Broekhuizen LN, Lemkes BA, Mooij HL, et al. Effect of sulodexide on endothelial glycocalyx and vascular permeability in patients with type 2 diabetes mellitus. Diabetologia. 2010;53(12):2646–2655. doi: 10.1007/s00125-010-1910-x. PubMed DOI PMC

Mannello F, Ligi D, Raffetto JD. Glycosaminoglycan sulodexide modulates inflammatory pathways in chronic venous disease. Int Angiol. 2014;33(3):236–242. PubMed

Mannello F, Ligi D, Canale M, Raffetto JD. Sulodexide down-regulates the release of cytokines, chemokines, and leukocyte colony stimulating factors from human macrophages: role of glycosaminoglycans in inflammatory pathways of chronic venous disease. Curr Vasc Pharmacol. 2014;12(1):173–185. doi: 10.2174/1570161111666131126144025. PubMed DOI

Ligi D, Mosti G, Croce L, Raffetto JD, Mannello F. Chronic venous disease—part I: inflammatory biomarkers in wound healing. Biochim Biophys Acta. 2016;1862(10):1964–1974. doi: 10.1016/j.bbadis.2016.07.018. PubMed DOI

Ligi D, Mosti G, Croce L, Raffetto JD, Mannello F. Chronic venous disease—part II: proteolytic biomarkers in wound healing. Biochim Biophys Acta. 2016;1862(10):1900–1908. doi: 10.1016/j.bbadis.2016.07.011. PubMed DOI

Ligi D, Benitez S, Croce L, et al. Electronegative LDL induces MMP-9 and TIMP-1 release in monocytes through CD14 activation: inhibitory effect of glycosaminoglycan sulodexide. Biochim Biophys Acta Mol Basis Dis. 2018;1864(12):3559–3567. doi: 10.1016/j.bbadis.2018.09.022. PubMed DOI

Shu J, Zeng LY, Lin KY, et al. Renal protective effects of sulodexide in diabetic rats and its anti-oxidative mechanism. Nan Fang Yi Ke Da Xue Xue Bao. 2009;29(4):778–780. PubMed

Gabryel B, Jarząbek K, Machnik G, et al. Superoxide dismutase 1 and glutathione peroxidase 1 are involved in the protective effect of sulodexide on vascular endothelial cells exposed to oxygen-glucose deprivation. Microvasc Res. 2016;103:26–35. doi: 10.1016/j.mvr.2015.10.001. PubMed DOI

De Felice F, Megiorni F, Pietrantoni I, et al. Sulodexide counteracts endothelial dysfunction induced by metabolic or non-metabolic stresses through activation of the autophagic program. Eur Rev Med Pharmacol Sci. 2019;23(6):2669–2680. doi: 10.26355/eurrev_201903_17415. PubMed DOI

Masola V, Onisto M, Zaza G, Lupo A, Gambaro G. A new mechanism of action of sulodexide in diabetic nephropathy: inhibits heparanase-1 and prevents FGF-2-induced renal epithelial-mesenchymal transition. J Transl Med. 2012;10:213. doi: 10.1186/1479-5876-10-213. PubMed DOI PMC

Xu G, Qin Q, Yang M, Qiao Z, Gu Y, Niu J. Heparanase-driven inflammation from the AGEs-stimulated macrophages changes the functions of glomerular endothelial cells. Diabetes Res Clin Pract. 2017;124:30–40. doi: 10.1016/j.diabres.2016.12.016. PubMed DOI

Giurdanella G, Lazzara F, Caporarello N, et al. Sulodexide prevents activation of the PLA2/COX-2/VEGF inflammatory pathway in human retinal endothelial cells by blocking the effect of AGE/RAGE. Biochem Pharmacol. 2017;142:145–154. doi: 10.1016/j.bcp.2017.06.130. PubMed DOI

Matuska J, Benova K. Development of wall stiffness parameters in diabetes mellitus type II—evaluation of therapeutic effect of sulodexide vs naftidrofuryl: an open controlled 2-year study. Vasa-Eur J Vasc Med. 2017;46:30. doi: 10.1024/0301-1526/a000651. DOI

Cha JJ, Kang YS, Hyun YY, et al. Sulodexide improves renal function through reduction of vascular endothelial growth factor in type 2 diabetic rats. Life Sci. 2013;92(23):1118–1124. doi: 10.1016/j.lfs.2013.04.008. PubMed DOI

Tiurenkov IN, Voronkov AV, Slietsans AA, Snigur GL. Effects of mexidol and sulodexide on the level of specific markers of endothelial dysfunction in animals with experimental diabetes mellitus. Eksp Klin Farmakol. 2012;75(5):14–16. PubMed

Raffetto JD, Calanni F, Mattana P, Khalil RA. Sulodexide promotes arterial relaxation via endothelium-dependent nitric oxide-mediated pathway. Biochem Pharmacol. 2019;166:347–356. doi: 10.1016/j.bcp.2019.04.021. PubMed DOI PMC

Condorelli M, Chiariello M, Dagianti A, et al. IPO-V2: a prospective, multicenter, randomized, comparative clinical investigation of the effects of sulodexide in preventing cardiovascular accidents in the first year after acute myocardial infarction. J Am Coll Cardiol. 1994;23(1):27–34. doi: 10.1016/0735-1097(94)90498-7. PubMed DOI

Peterkova V, Mishina I, Sherbacheva L. Sulodexide in the treatment of diabetic nephropathy in children. Diabetes (Mosk) 1999;3:31–33.

Higgins JP, Thomas J, Chandler J, et al. Cochrane handbook for systematic reviews of interventions, version 6.0. New York: Wiley; 2019.

Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. doi: 10.1136/bmj.l4898. PubMed DOI

Balduzzi S, Rucker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health. 2019;22(4):153–160. doi: 10.1136/ebmental-2019-300117. PubMed DOI PMC

R Core Team. A language and environment for statistical computing. 2015. R foundation for statistical computation, Vienna, Austria. https://www.R-project.org/. Accessed 17 Mar 2020.

Higgins JP, Li T, Deeks JJ, et al. Choosing effect measures and computing estimates of effect, version 6.0. In: Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page M, et al., editors. Cochrane handbook for systematic reviews of interventions. New York: Wiley; 2019. pp. 143–176.

Lipsey MW, Wilson DB. Practical meta-analysis. Thousand Oaks: SAGE; 2001.

Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014;14:135. doi: 10.1186/1471-2288-14-135. PubMed DOI PMC

Chen S, Wei M, Gao Y, et al. A randomized controlled trial of sulodexide for early diabetic nephropathy. Chin J Evid Based Med. 2008;8(3):162–166. doi: 10.7507/1672-2531.20080037. DOI

Hu M, Lv B, Meng Y, Zhou J, Xu X, Xiao X. Therapeutic effects of sulodexide combined with irbesartan on elderly patients with diabetic nephropathy. Pract Geriatr. 2009;23(4):276–278.

Wang T-J, Wang Z-S, Yang F. Clinical observation of sulodexide in treatment of type 2 diabetes with early nephropathy. Med Pharm World. 2009;11:769–771.

Hu M, Lv B, Meng Y, Zhou J, Xu X, Xiao X. Therapeutic effects of perindopril combined with sulodexide on elderly early patients with diabetic nephropathy. Southwest Nat Defence Med. 2010;20:501–503.

Liu S. Therapeutic effects of sulodexide combined with benazapril on patients with diabetic kidney disease. Chin J Diffic Compl Cas. 2011;10:21–22.

Ma J, Jiang H, Cui Q, Song B. Clinical observation of sulodexide in reducing microalbumi-nuria in diabetic nephropathy patients. Mod Prev Med. 2011;38:2918–2919.

Zhang H, Kang P, Li J, et al. Study of the effect of Chulo on albuminuria in diabetic nephropathy. Med J Integr Tradit Chin West Med. 2011;20:405–406.

Huo S, Huang M, Liu Y. Clinical observation of sulodexide in treatment of in reducing proteinuria in type 2 diabetic nephropathy patients. Hebei Med J. 2014;36:191–192.

Chen L, Yang R. Effect of sulodexide on urine protein excretion in type 2 diabetes with proteinuria. Med J Wuhan Univ. 2015;34:450–452.

Rubbi F, Caramazza R, Boccia S, et al. The effects of sulodexide on diabetic retinopathy. Minerva Cardioangiol. 2000;48(Suppl 1):81–82.

Shadrichev F. The effect of diabetic nephropathy therapy with “Vessel Due F” (sulodexide) on the risk of intraocular hemorrhages in patients with proliferative diabetic retinopathy. Ophthalmol Gazette. 2009;2(2):49–53.

Song JH, Chin HS, Kwon OW, Lim SJ, Kim HK, DRESS Research Group Effect of sulodexide in patients with non-proliferative diabetic retinopathy: diabetic retinopathy sulodexide study (DRESS) Graefes Arch Clin Exp Ophthalmol. 2015;253(6):829–837. doi: 10.1007/s00417-014-2746-8. PubMed DOI PMC

Belcaro G, Dugall M, Bradford HD, et al. Recurrent retinal vein thrombosis: prevention with aspirin, Pycnogenol®, ticlopidine, or sulodexide. Minerva Cardioangiol. 2019;67(2):109–114. doi: 10.23736/S0026-4725.19.04891-6. PubMed DOI

Utratová J, Mayer J, Elbl L, Vorlícek J, Prásek J. Experience with sulodexide (Vessel Due F) in diabetics with ischemic disease of the lower extremities. Vnitr Lek. 1993;39(6):575–580. PubMed

Bregovsky V, Zalesskaya A. The use of sulodexide in obliterating atherosclerosis of the lower extremities in patients with diabetes mellitus. Prob Endocrinol. 1998;44(4):16–18. doi: 10.14341/probl199844416-18. DOI

Koblik T, Sieradzki J, Sendur R, et al. The effect of insulin and sulodexide (Vessel Due F) on diabetic foot syndrome: pilot study in elderly patients. J Diabetes Complicat. 2001;15(2):69–74. doi: 10.1016/s1056-8727(00)00134-3. PubMed DOI

Coccheri S, Scondotto G, Agnelli G, Palazzini E, Zamboni V, Arterial Arm of the Suavis (Sulodexide Arterial Venous Italian Study) Group Sulodexide in the treatment of intermittent claudication. Results of a randomized, double-blind, multicentre, placebo-controlled study. Eur Heart J. 2002;23(13):1057–1065. doi: 10.1053/euhj.2001.3033. PubMed DOI

Moldovan C, Marc F, Farcaş D. Sulodexide treatment in patients with type 2 diabetes mellitus and intermittent claudication. Eur J Int Med. 2011;22:S63. doi: 10.1016/S0953-6205(11)60259-8. DOI

Katorkin SE. Significance of endothelial protection in treatment of patients with class c6 chronic venous disease and type 2 diabetes mellitus. Angiol Sosud Khir. 2015;21(3):99–102. PubMed

Zakharova NO, Bulgakova SV, Katorkin SE, Melnikov MA, Treneva EV, Nikolaeva AV. The treatment of elderly and senile patients with venous trophic ulcers and type 2 diabetes mellitus. Adv Gerontol. 2017;30(6):917–924. PubMed

Solini A, Carraro A, Barzon I, Crepaldi G. Therapy with glycosaminoglycans lowers albumin excretion rate in non-insulin dependent diabetic patients with macroalbuminuria. Diabetes Nutr Metab. 1994;7(5):304–307.

Velussi M, Cernigoi A, Dapas F, De Monte A. Glycosaminoglycans oral therapy reduces microalbuminuria, blood fibrinogen levels and limb arteriopathy clinical signs in patients with non-insulin dependent diabetes mellitus. Diabetes Nutr Metab. 1996;9(2):53–58.

Dedov I, Shestakova M, Vorontzov A, Palazzini E. A randomized, controlled study of sulodexide therapy for the treatment of diabetic nephropathy. Nephrol Dial Transplant. 1997;12(11):2295–2300. doi: 10.1093/ndt/12.11.2295. PubMed DOI

Perušičová J, Škrha J. The effect of sulodexide, a glycosaminoglycan, on albuminuria in diabetic patients. Vnitr Lek. 1997;43(11):748–752. PubMed

Poplawska A, Szelachowska M, Topolska J, Wysocka-Solowie B, Kinalska I. Effect of glycosaminoglycans on urinary albumin excretion in insulin-dependent diabetic patients with micro- or macroalbuminuria. Diabetes Res Clin Pract. 1997;38(2):109–114. doi: 10.1016/s0168-8227(97)00096-x. PubMed DOI

Shestakova MV, Chugunova LA, Vorontsov AV, Dedov II. The efficacy of sulodexide—a low-molecular heparin—in the therapy of diabetic nephropathy. Ter Arkh. 1997;69(6):34–37. PubMed

Škrha J, Perušičová J, Pont'uch P, Okša A. Glycosaminoglycan sulodexide decreases albuminuria in diabetic patients. Diabetes Res Clin Pract. 1997;38(1):25–31. doi: 10.1016/s0168-8227(97)00076-4. PubMed DOI

Solini A, Vergnani L, Ricci F, Crepaldi G. Glycosaminoglycans delay the progression of nephropathy in NIDDM. Diabetes Care. 1997;20(5):819–823. doi: 10.2337/diacare.20.5.819. PubMed DOI

Sorrenti G, Grimaldi M, Canova N, Palazzini E, Melchionda N. Glycosaminoglycans as a possible tool for micro- and macroalbuminuria in diabetic patients. A pilot study. J Int Med Res. 1997;25(2):81–86. doi: 10.1177/030006059702500204. PubMed DOI

Szelachowska M, Poplawska A, Topolska J, Kinalska I, Grimaldi M. A pilot study of the effect of the glycosaminoglycan sulodexide on microalbuminuria in type I diabetic patients. Curr Med Res Opin. 1997;13(9):539–545. doi: 10.1185/03007999709113327. PubMed DOI

Rasovskiĭ BL, Tarasov AV, Trel'skaia N, Severina TI, Chernykh EF. Sulodexide in the treatment of diabetic nephropathy. Klin Med (Mosk) 1998;76(7):40–42. PubMed

Škrha J, Perušičová J, Kvasnička J, Hilgertová J. The effect of glycosaminoglycan sulodexide on oxidative stress and fibrinolysis in diabetes mellitus. Sb Lek. 1998;99(2):103–109. PubMed

Zalevskaia AG, Astamirova KhS, Karpova IA, Popova SG. A trial of the use of the low-molecular heparin sulodexide in the therapy of diabetic nephropathy. Ter Arkh. 1998;70(3):71–74. PubMed

Oksa A, Pontuch P, Kratochvilova H. The effect of glycosaminoglycan sulodexide on albuminuria in patients with diabetes mellitus. Bratisl Lek Listy. 1999;100(9):486–489. PubMed

Sun M, Tian L. Clinical study on type II diabetic nephropathy treated with sulodexide. Chi J Chin New Drugs J. 1999;8:408–410.

Lichiardopol R, Ionescu-Tirgoviste C, Serban V, Dumitrescu C, Mota M, Ghise G. The effect of sulodexide on albuminuria in a group of patients with diabetes. Rom J Diabetes Nutr Metab Dis. 2001;2:28–31.

Gambaro G, Kinalska I, Oksa A, et al. Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: the Di.N.A.S. randomized trial. J Am Soc Nephrol. 2002;13(6):1615–1625. doi: 10.1097/01.asn.0000014254.87188.e5. PubMed DOI

Achour A, Kacem M, Dibej K, Skhiri H, Bouraoui S, El May M. One year course of oral sulodexide in the management of diabetic nephropathy. J Nephrol. 2005;18(5):568–574. PubMed

Sulikowska B, Olejniczak H, Muszynska M, et al. Effect of sulodexide on albuminuria, NAG excretion and glomerular filtration response to dopamine in diabetic patients. Am J Nephrol. 2006;26(6):621–628. doi: 10.1159/000098195. PubMed DOI

Heerspink HL, Greene T, Lewis JB, et al. Effects of sulodexide in patients with type 2 diabetes and persistent albuminuria. Nephrol Dial Transplant. 2008;23(6):1946–1954. doi: 10.1093/ndt/gfm893. PubMed DOI

Blouza S, Dakhli S, Abid H, et al. Efficacy of low-dose oral sulodexide in the management of diabetic nephropathy. J Nephrol. 2010;23(4):415–424. PubMed

Mao L, Zhong X. Effect of sulodexide combined with benazepril on urinary albumin in patients with type 2 diabetes. Chin Mod Med. 2010;17:68–69.

Jian R, Jie S, Can H. Effect of sulodexide on microalbuminuria of the third stage of type 2 diabetic nephropathy. Mod Med J Chin. 2010;11:20.

Wang H. Effect of sulodexide in diabetic nephropathy. Prac J Med Pharm. 2010;27:315–316.

Lewis EJ, Lewis JB, Greene T, et al. Sulodexide for kidney protection in type 2 diabetes patients with microalbuminuria: a randomized controlled trial. Am J Kidney Dis. 2011;58(5):729–736. doi: 10.1053/j.ajkd.2011.06.020. PubMed DOI

He X, Ge Z. Curative effect of sulodexide in diabetic nephropathy patients. Clin Foc. 2012;27:1626–1627.

Packham DK, Wolfe R, Reutens AT, et al. Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy. J Am Soc Nephrol. 2012;23(1):123–130. doi: 10.1681/ASN.2011040378. PubMed DOI PMC

Kang Z. Study on effect of sulodexide in treatment of diabetic nephropathy stage III. Guide Chin Med. 2013;11:25–28.

Xiong Y. Treatment of sulodexide on albuminuria in early diabetic nephropathy. J Jianghan Univ (Nat Sci Ed) 2014;42(3):90–92.

Satirapoj B, Kaewput W, Supasyndh O, Ruangkanchanasetr P. Effect of sulodexide on urinary biomarkers of kidney injury in normoalbuminuric type 2 diabetes: a randomized controlled trial. J Diabetes Res. 2015;2015:172038. doi: 10.1155/2015/172038. PubMed DOI PMC

Zilişteanu DS, Atasie T, Voiculescu M. Efficacy of long-term low-dose sulodexide in diabetic and non-diabetic nephropathies. Rom J Intern Med. 2015;53(2):161–169. doi: 10.1515/rjim-2015-0022. PubMed DOI

Dakhli S, Khedher A, Borni Z, Achour A, Hachicha J. A clinical experience on sulodexide in the treatment of patients with diabetic nephropathy. J Nephrol Ther. 2016;7(1):1000284. doi: 10.4172/2161-0959.1000284. DOI

Li H, Ke W, Liu J, He X, Jr, Liu L, Li Y. Effect of intravenous and oral therapy with sulodexide on diabetic nephropathy. Diabetes. 2017;66:A597.

Pisano L, Moronesi F, Falco F, et al. The use of sulodexide in the treatment of peripheral vasculopathy accompanying metabolic diseases. Controlled study in hyperlipidemic and diabetic subjects. Thromb Res. 1986;41(1):23–31. doi: 10.1016/0049-3848(86)90276-8. PubMed DOI

Piva I, Lora L, Baso A, Erle G. Controlled study of the effect of sulodexide on peripheral diabetic macroangiopathy. G Clin Med. 1985;66(1–2):37–45. PubMed

Arsenio L, Strata A. Hyperlipidaemias in diabetes. Therapeutic effects of a parenterally administered glucosaminoglycan: sulodexide (Vessel Due) Clin Trials J. 1987;24:312–321.

Szafilk J, Kamińska A. Usefulness of Vessel Due F (sulodexide) in treatment of patients with diabetic retinopathy, senile macular degeneration and retinal vein occlusion. Okulistyka. 2000;3:1–4.

d’Aloia A, Dati M, Della Corte M, Romano M, Lanza M, Romano A. Assessment of the effectiveness of sulodexide on diabetic patients. Boll Oculistica. 2001;80(1):37–41.

Karimov K, Shakhmaliyeva A. Effect of sulodexide on non-proliferative diabetic retinopathy. Azerbaijan Med J. 2002;1:72–76.

Li R, Xing J, Mu X, et al. Sulodexide therapy for the treatment of diabetic nephropathy, a meta-analysis and literature review. Drug Des Devel Ther. 2015;9:6275–6283. doi: 10.2147/DDDT.S87973. PubMed DOI PMC

Yan W, Zhou B, Shen Y, Xu G. Antioxidant and antithrombotic therapies for diabetic kidney disease. Iran J Kidney Dis. 2015;9(6):413–420. PubMed

Lamblova K, Mlcoch T, Mazalova M, Dolezal T. Cost-effectiveness analysis of sulodexide in patients with non-proliferative diabetic retinopathy in the Czech Republic. Value Health. 2016;19(7):A568. doi: 10.1016/j.jval.2016.09.1283. DOI

Tokmakova AY, Milenkaya T, Chirkova L, Arbuzova M, Antsiferov M. The use of the drug Wessel Duet F in the complex treatment of lesions of the lower extremities in patients with type II diabetes. Prob Endocrinol. 1999;45(3):14–18. doi: 10.14341/probl11760. DOI

Klisarova A, Bihchelian H, Koeva L. Planary bone scintigraphy of the foot in the diabetics with peripheral macroangiopathy, treated with sulodexide (Vessel Due F) Rentgenol Radiol. 2000;39(4):281–284.

Svetukhin AM, Zemlianoĭ AB, Orudzheva SA, et al. Experience in the use of vessel due F (sulodexide) in patients with suppurative-necrotic forms of diabetic foot without critical ischemia. Ter Arkh. 2001;73(4):31–33. PubMed

Mozgovaya E, Pecherina L. Sulodexide efficacy in complex therapy and prevention of gestational toxicosis (gestosis) in patients with type 1 diabetes mellitus. Farmateka. 2006;3:128–133.

Olde Engberink RH, Vogt L. The renoprotective effects of sulodexide. Drug Des Devel Ther. 2016;10:1233–1234. doi: 10.2147/DDDT.S102814. PubMed DOI PMC

Shustov SB. Controlled clinical trial on the efficacy and safety of oral sulodexide in patients with peripheral occlusive arterial disease. Curr Med Res Opin. 1997;13(10):573–582. doi: 10.1185/03007999709113331. PubMed DOI

Apollonio A, Antignani PL, Di Salvo M, et al. A large Italian observational multicentre study on vascular ulcers of the lower limbs (Studio Ulcere Vascolari) Int Wound J. 2016;13(1):27–34. doi: 10.1111/iwj.12216. PubMed DOI PMC

Arcangeli A, Pedone T, Crescenti C, Ianni L. Microalbuminuria and type-II diabetes: clinical efficacy of sulodexide. Preliminary data. Minerva Cardioangiol. 2000;48(11 Suppl 2):72–73.

Piaggesi A, Abbruzzese L, Mattaliano C, et al. Sulodexide as adjunctive therapy in diabetic foot patients with critical limb ischemia treated with percutaneous transluminal angioplasty. Int J Low Extrem Wounds. 2014;13(2):103–109. doi: 10.1177/1534734614534442. PubMed DOI

Gohel MS, Taylor M, Earnshaw JJ, Heather BP, Poskitt KR, Whyman MR. Risk factors for delayed healing and recurrence of chronic venous leg ulcers–an analysis of 1324 legs. Eur J Vasc Endovasc Surg. 2005;29(1):74–77. doi: 10.1016/j.ejvs.2004.10.002. PubMed DOI

Coccheri S, Bignamini AA. Pharmacological adjuncts for chronic venous ulcer healing. Phlebology. 2016;31(5):366–367. doi: 10.1177/0268355515619562. PubMed DOI PMC

Gambaro G. Discounting the efficacy of sulodexide in diabetic nephropathy is premature. Am J Kidney Dis. 2012;60(1):169–170. doi: 10.1053/j.ajkd.2012.01.029. PubMed DOI

Coccheri S. Game not over for sulodexide. Am J Kidney Dis. 2012;59(3):467. doi: 10.1053/j.ajkd.2011.12.010. PubMed DOI

Rozita M, Mohd Shahrir M, Loo C, et al. Glycosaminoglycans (sulodexide) for resistant heavy proteinuria of chronic glomerulonephritides. Nephrology. 2008;13(Suppl 1):A55.

Kozlova L, Khokhlov R, Akhmedzhanov N. Clinical efficacy of glycosaminoglycans in patients with diabetes mellitus and ischemic heart disease. Rational Pharmacother Card. 2011;7(5):584–590. doi: 10.20996/1819-6446-2011-7-5-584-590. DOI

Marcoux R, Larrat E, Taubman A, Wilson J. Screening for peripheral arterial disease. J Am Pharm Assoc (Wash) 1996;NS36:370–373. doi: 10.1016/S1086-5802(16)30076-6. PubMed DOI

Golomb BA, Dang TT, Criqui MH. Peripheral arterial disease: morbidity and mortality implications. Circulation. 2006;114(7):688–699. doi: 10.1161/CIRCULATIONAHA.105.593442. PubMed DOI

Heerspink HJL, Greene T, Tighiouart H, et al. Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials. Lancet Diabetes Endocrinol. 2019;7(2):128–139. doi: 10.1016/S2213-8587(18)30314-0. PubMed DOI

Inker LA, Heerspink HJL, Tighiouart H, et al. GFR slope as a surrogate end point for kidney disease progression in clinical trials: a meta-analysis of treatment effects of randomized controlled trials. J Am Soc Nephrol. 2019;30(9):1735–1745. doi: 10.1681/ASN.2019010007. PubMed DOI PMC

Olde Engberink RH, Heerspink HJ, de Zeeuw D, Vogt L. Blood pressure-lowering effects of sulodexide depend on albuminuria severity: post hoc analysis of the sulodexide microalbuminuria and macroalbuminuria studies. Br J Clin Pharmacol. 2016;82(5):1351–1357. doi: 10.1111/bcp.13062. PubMed DOI PMC

Bignamini AA, Matuška J. Sulodexide for the symptoms and signs of chronic venous disease: a systematic review and meta-analysis. Adv Ther. 2020;37(3):1013–1033. doi: 10.1007/s12325-020-01232-1. PubMed DOI PMC

Gaddi A, Galetti C, Illuminati B, Nascetti S. Meta-analysis of some results of clinical trials on sulodexide therapy in peripheral occlusive arterial disease. J Int Med Res. 1996;24(5):389–406. doi: 10.1177/030006059602400501. PubMed DOI

Shang H-X, Zhao J-Y, Shen X, et al. The efficacy and safety of sulodexide in patients with diabetic nephropathy: a meta-analysis of randomized controlled trials. Int J Clin Exp Med. 2016;9(7):12481–12491.